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O

ur objective is to characterize the development of the
literature on hypertension and cognitive functioning from a
historical perspective. This goal was stimulated by the review on
“Historical Trends and Milestones in Hypertension Research” in
the October 2012 issue of Hypertension.1 Our specific aims are
threefold: (1) to trace and describe the history of this area of
research; (2) to identify milestones in knowledge and methods;
and (3) to discuss briefly how this literature translates into
patient care. The topic is of major relevance to research and
practice because hypertension is a well-known risk factor for
decline in cognitive performance within the normal range of
cognitive functioning, mild cognitive impairment (MCI) and
dementia. It is important to emphasize 3 features of the review:
(1) it is not designed as a critical review of the literature, but
rather to describe the historical influences on our current knowledge base (poor, mediocre and outstanding papers from the past
have all shaped our present); (2) word-count limitations require
that we omit statistical detail except to emphasize effect sizes in
pivotal papers; and (3) each milestone topic is addressed by
noting the earliest work then followed by examples of papers
representing pivotal events. A number of comprehensive reviews of this literature are available,2–6 including a seminal
paper summarizing the formative years of this research.7 Please
see http://hyper.ahajournals.org for citations to additional reviews of the literature and papers published in Hypertension. We
recognize the importance of the emerging literature on hypotension and cognitive function, but refer the readers to previous
reviews which include this topic.8–10

Measurement of Cognitive Functioning
In this paper, the term cognitive performance is used to
describe the outcome of studies measuring a full range of
ability from low to high. The term cognitive functioning is
used to describe, more generally, findings with respect to
cognitive performance, MCI, or dementia. Cognitive deficit is
used in a comparative sense, hypertensive individuals compared to some other group of subjects. The term impairment
is used to indicate clinically significant cognitive dysfunction.

Lezak et al11 provide a compendium of over 700 psychometric tests and subtests. They describe behaviors required to
perform the test, the latent abilities that the tests purport to
measure, eg, working memory, attention, and executive
functioning. Classic neuropsychological texts describe how
tests and the latent cognitive constructs they measure are used
to make inferences about the hemisphere, locus, and extent of
brain injury.12 Figure 1 shows an example of a hypothetical
study in which tests are being used to explore the hypothesis
that hypertension is more strongly associated with executive
functioning13 and that this phenomenon is associated with
reduced cerebral blood flow (CBF) to the frontal and prefrontal brain areas, but not to other brain areas.14 Executive
functioning (EF) can be defined as the ability to integrate and
organize current knowledge to acquire new concepts and
strategies that allow effective application of current information to new anticipated and unanticipated situations.13 It is
important to note that more than 1 test is used to identify a
latent cognitive variable, eg, EF.12,13 Tests that do and do not
measure EF must be included in the test battery, and it is the
pattern of results that provides evidence for or against the
hypothesis. This hypothetical study includes measures of
regional CBF and MRI. A paper by Haier et al15 provides an
example of this approach.

Details of the Literature Search
The online databases and search engines that we used initially
to identify papers were PubMed, Medline, ScienceDirect,
PsychINFO, PsyARTICLES, Psychology Abstracts, CINAHL,
and the Cochrane Library. The basic requirement for a paper was
that cognitive performance, MCI, or dementia had to be an
outcome measure. Search terms relating to outcome measures
were cognition, cognitive performance, cognitive functioning, MCI, cognitive dysfunction, dementia, Alzheimer’s
disease (AD), and vascular dementia (VaD). Search terms
related to the predictor side were: hypertension, hypotension, orthostatic hypertension, orthostatic hypotension,
high blood pressure (BP), low BP, pulse pressure, pulse
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Figure 1. In this hypothetical example, objective scores on tests are used to index theoretical constructs that are in turn used as a
basis for inferences about brain function. In
this example, only 1 brain area other than the
prefrontal/frontal is being considered. Test
details may be found in Lezak et al.11
WAIS!Wechsler Adult Intelligence Scale;
WMS!Wechsler Memory Scale.

WMS Visual Memory

wave velocity, augmentation index, central BP, and antihypertensive medication/drug/treatments. Additional qualifying papers were obtained by reading papers identified by these
searches. Clinical trials of antihypertensive medications and
lifestyle changes were included in the counts of research papers,
as were nontrial studies comparing antihypertensive medications
with respect to cognitive performance.
For the papers published in Hypertension we used the same
search methods but also obtained a record of published papers
from Hypertension staff. In this brief historical outline, we
discuss some papers that relate hypertension/BP to structural and
functional change in the brain, but that did not include cognitive
measures. These papers were not included in the counts on
Figure 2. We searched published articles between 1900 and
2011. We then used each article retrieved to trace back to the
first published article on the topic and to find additional
papers. Case studies were not included in the counts, and
counts were not based on judgments as to adequate controls.

in 1997, a dramatic rise in published articles. Of the 683 papers
included in Figure 2, 88 used dementia as a sole outcome and the
balance used cognitive functioning, including or excluding
dementia. The growth in publications on cognitive performance
parallels the growth of publications in science, including hypertension research in general.1 This profile rise in publications in
general was paralleled by Hypertension (not shown) after a later
beginning (1982). The lag reflects the fact that much of the
earlier literature was published in psychology, neurology, and
gerontology journals. Publication in journals on hypertension
was important with respect to attracting the attention of the
medical community to research on hypertension and cognitive
functioning.

Milestone Events and Periods

Kotchen1 compiled a list of noteworthy discoveries, authors, and
papers in hypertension research using as a criterion recipients of
the Annual Council for High Blood Pressure Awards. This was
not possible for our purposes because hypertension-cognition
research is multidisciplinary. No single organization gives
awards for research on hypertension with this focus. Conse-

Growth in Publications

Figure 2 shows the growth in peer review publications beginning in 1962. There was slow initial growth and then, beginning
300
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Figure 2. Estimated number of published papers (including clinical trials) on hypertension and cognitive function appearing in the literature between 1962 and 2011.
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quently, we identify milestone events within research periods in
terms of major research emphases during that period. Dates are
approximate and the work beginning in one period continues
into the next. The papers we cite are illustrative of research
trends. Exclusion of published papers does not indicate that they
are of secondary importance.

The Null Period (Pre-1928)

Hypertension was first measured in 1733.1 The search for
causes of hypertension was well underway by 1844,1 but
there was little specific concern about hypertension and
cognition until 1928. Even then studies were observational
and concerned with the brain.

Clinical Observation Period (1928 –1947)
Observation in the clinic focused on hypertension as a
possible reason for changes in brain structure and function in
persons who came to clinics or hospitals with overt cognitive
and psychiatric impairments and relatively high levels of
sustained, untreated hypertension. Kotchen uses the term
therapeutic nihilism1 (p. 527) to describe attitudes toward
treatment at this time. First-generation drugs were available,
but despite mounting evidence that hypertension was related
to risk of stroke and heart disease, there was a prevailing
reservation about treating hypertension. Kotchen notes that in
1931, “Paul Dudley White, an eminent Boston cardiologist,
wrote that hypertension may be an important compensatory
mechanism which should not be tampered with, even where it
is certain that we could control it”1 (p. 527). In 1931, Hay
wrote in the British Medical Journal that “the greatest danger
to a man with high blood pressure lies in its discovery,
because some fool is certain to try to reduce it”1 (p. 527).

Clinical Case Study Period (1947–1962)
The first case studies on hypertension and cognitive functioning
began circa 1947, at about the time when Page introduced
“‘mosaic theory’ to explain the etiology of hypertension”1 (p.
525). These studies involved blind clinical neuropsychological
evaluation of small numbers of patients (eg, n!14)16 with very
high uncontrolled BP (157–202 mmHg systolic and 99 –130
mmHg diastolic),17 and symptoms of brain damage. Following
several studies indirectly related to hypertension,2 Apter et al16
in 1951 and Reitan17 in 1954 published several pioneering
papers. They concluded that their hypertensive patients performed in a manner similar to brain-damaged individuals,
particularly persons with EF disabilities, ie, the patients demonstrated an inability to integrate, organize, problem solve, and
engage in meaningful and thoughtful action. Obviously this
description mischaracterizes the cognitive functioning of hypertensive individuals typically seen in the office or clinic today.
Indeed, subsequent work in 198718 found no evidence of
clinically significant cognitive impairment in persons manifesting uncomplicated primary hypertension. This is a generally
agreed on conclusion in reviews of this literature.2–5,7

Descriptive Study Period (1962–1972)
The first widely cited case-control study of hypertension and
cognitive functioning was published in 1964.19 Spieth reported that, compared to their normotensive counterparts

(n!560), hypertensive commercial air traffic controllers and
aircraft pilots (n!17) performed at a lower level on multiple
measures of speed of performance. There was some research
indirectly related to hypertension done prior to this period,2
but it was not focused on hypertension specifically. Spieth19
concluded that the differences observed between cases and
controls could be due to stress related to license recertification rather than brain injury. This caveat represents an early
awareness that factors other than biological phenomena can
explain relations between hypertension and cognitive ability,
and that confounding by stress, anxiety, depression, and
psychosocial variables are more likely to occur when hypertensive individuals are aware of their diagnosis and these
confounders are not controlled.2,7,8,20
Possibly the event with the greatest impact on this period and
the following decade of work was the publication of the Duke
University Longitudinal Study of Hypertension in Science in
1971 by Wilkie and Eisdorfer.21 The sample was small (total
N!202), all subjects were being treated and controls for
hypertension-related comorbidity and risk factors widely used in
current research were not used. For persons 60 to 69 years of age
at baseline, a major hypertension-associated longitudinal decline
in Wechsler Adult Intelligence Scale (WAIS) Performance
Scaled Scores was observed over 10 years. Hypertension was
defined as diastolic BP "105 mmHg which is equivalent to
Stage 2 hypertension by current definitions. In contrast, there
was a trivial and nonsignificant decline in WAIS Performance
Scaled Scores for study participants who exhibited “normal” BP,
diastolic BP #95 mmHg. Change over 10 years was examined
for subjects 70 to 79 years of age, but none of the Stage 2
hypertensive individuals returned to be tested after the 10-year
follow-up. The first elements of the findings and methodological
issues with longitudinal research were seen in this study. The
hypertensive individuals showed decline on measures of fluid
intellect, ie, solving of novel problems and tests of visual-spatial
organization and constructional abilities under time constraints,21 but subject attrition from baseline was observed for
the poorest performing individuals in the poorest cardiovascular
health. Findings reported for “borderline hypertension” were not
replicated in later research with better controls2 and thus are not
described.
Wilkie and Eisdorfer explained longitudinal decline for the
Stage 2 hypertensive group in terms of cerebral ischemia and
resulting hypoperfusion. Five years later (1976) Hagberg and
Ingvar22 reported that reduction in cognitive performance in
dementia was associated with abnormalities in CBF, and it is
now clear that regional CBF studies are central to the studies
of blood flow mechanisms intervening between hypertension
and performance deficits.3,23,24
Both systolic and diastolic BP mm Hg were inversely
associated with levels of performance on WAIS Performance
Scale subtests and positively related to the amount of decline
in these scores over 10 years. Consequently, a dose-responserelation between BP and cognitive performance, important
for arguments with regard to causal associations, was established. Associations between higher BP and lower cognitive
functioning were observed in many of the studies that
followed over the years and these relations were robust when
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adjusted for age, multiple other demographic factors, and
hypertension-associated risk factors and comorbidity.5,25,26–30
The use of hypertension diagnostic categories and BP as
predictor variables has been very important for the continuity
of research in this area because cut values defining hypertension have progressively declined over the years. The emphasis on the diagnostic importance of BP has swung from
diastolic to systolic BP and finally to a recognition of the
importance of both measures.31 In general, both have been
related to cognitive functioning in the cognitive literature
regardless of age at the time of BP assessment.5,25,27 The
importance of the Duke Longitudinal Study21 was its originality and the fact that it stimulated many of the crosssectional and longitudinal studies that followed. For example,
in 1975 baseline data collection in the Maine Syracuse
Longitudinal Study (MSLS) of hypertension and cognitive
performance2,28,29 began as a direct response to the Duke
study.21 Longitudinal MSLS data resulting from 2 very long
follow-up periods, 1428 and 19 years,29 are summarized in a
section on longitudinal studies which follows after our
synopsis of the cross-sectional period of study.

Descriptive-Cross-Sectional
Period (1973–1982)
After the Duke study, longitudinal data on cognitive performance did not appear again in the literature for 15 years.
Published studies were predominantly cross-sectional,2–7,15,25
and 3 research emphases were dominant: (1) descriptive studies
designed to improve controls, ie, exclusion, adjustment for
confounders, and sensitivity analyses; (2) further examination of
age by hypertension interactions with regard to cognitive performance in young and middle-aged adults; and (3) determination of which specific cognitive abilities are vulnerable to
hypertension. A majority of reports indicated that relations
between hypertension/BP and cognition were robust regardless
of additional controls.5 It became clear that associations between
hypertension/BP and cognition were seen for older as well as
younger adults and that parental history of hypertension was a
risk factor for poorer cognitive performance.5
Waldstein’s argument for more attention to be paid to
hypertension and cognition in young adults and children was
reinforced by papers and reviews appearing between 2002
and 2010 that described deficits in attention and EF, among
other cognitive abilities, in young children and adolescents,32
and the adverse consequences of hypertension for the developing brain.33
With respect to hypertension-related cognitive abilities, the
cross-sectional literature indicated hypertension/BPassociated performance deficits on psychometric tests measuring fluid intelligence, EF, learning and memory, attention,
perceptual-motor skills, psychomotor speed, motor function,
and visual-spatial-organizational skills with sparing of wellpracticed verbal abilities such as information and vocabulary
skills (crystallized ability) in nondemented individuals.5,7,8
EF has been singled out as particularly vulnerable to hypertension and rise in BP in some studies,4,14 but it is quite clear
that EF is difficult to separate from fluid intelligence.13
In almost all studies there are significant individual differences in performance levels,30 and cognitive deficits do not rise
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to clinically significant cognitive impairment in uncomplicated
primary hypertension.2,18,34 This may seem inconsistent with
findings of neurobiological changes in the brain based on
positron emission tomography (PET), MRI and CBF, but it must
be recognized that the compensatory capability of the brain and
the individual is significant12 as is indicated by recent regional
CBF studies by Jennings et al.24 The next time period marked a
move from cross-sectional work to prospective designs with
large community-based samples.

Prospective and Population
Studies (1982–1996)
The Framingham Heart Study (FHS) began in 1950. The first
FHS data on hypertension and cognition appeared in 1987.35
This large-sample study (n!2132) by Farmer and colleagues35 generated considerable attention because it reported
no associations between BP and multiple measures of cognitive performance in persons 59 to 89 years of age. These
negative findings were challenged because only one or two
BP measurements were taken concurrently with the assessment of cognitive function.36 In a second FHS study37 with
subjects of the same age, but stroke excluded (n!1993), BP
was measured over a 26-year period that overlapped with the
measurement of cognitive performance. Statistically significant inverse associations between BP and cognition were now
observed and the longer the exposure to hypertension, the
lower the cognitive performance. Given a significant graded
relation between level of cognitive deficit and the probability
of being on medication at the time of cognitive testing,
Farmer et al37 suggested that cognitive deficit may have been
associated with reduced adherence to drug treatment regimens rather than subvascular disease.
This conclusion was challenged in a 1993 paper36 by Elias
et al who used the FHS sample using a prospective design and
reaching back to a point in time when relatively fewer cases
of hypertension were treated.1 In the most important of 3
analyses, the independent variables were untreated systolic
and diastolic BP averaged over the first 8 FHS biennial
examinations (1950 –1964) for a subsample of 1485 individuals with 18% defined as hypertensive (BP !160/95 mm Hg).
BP ranged from 95 to 193 mm Hg systolic and 56 to 115
mm Hg diastolic. Averaged BP values were related to cognitive performance measured once 14 or 15 years after the BP
surveillance period when participants were 55 to 88 years of
age (1976 –1978). The outcome variables, 8 cognitive test
scores, were expressed in standardized (z) scores so that test
results could be directly compared across tests. With exclusion of persons with acute stroke and adjustment for age,
education, occupation, sex, alcohol consumption, and cigarette smoking, untreated systolic and diastolic BP values
averaged over this 1950 to 1964 surveillance period were
linearly and inversely associated with performance level,
including scores on the composite of all cognitive performance levels and tests of episodic verbal memory-immediate
recall, episodic verbal memory-delayed recall, working memory, and visual memory. The mean and standard deviation
(SD) for the distribution of z scores were 0 and 1, respectively, and regression coefficients were expressed in SD
units. Compared to participants with normal BP, the untreated
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hypertensive individuals performed 0.15 SD lower on the
composite score ("!$0.15), and deficits ranged between
0.25 ("!$0.25) and 0.18 ("!$0.18) for the various measures of memory with the lowest performance on episodic
verbal memory-immediate recall.
Although a prospective relation between BP and cognitive
performance was observed, it could be argued that events
during the 12- to 14-year interval between BP surveillance
and measurement of cognitive performance could have influenced the cognitive findings. Consequently, the analysis was
repeated with a smaller sample (n!1038; 7.5% hypertensive)
that remained untreated from the beginning of the FHS
(1950) through the neuropsychological examination period
(1976 –1978). Again, linear inverse associations were observed for systolic and diastolic BP averaged over the 15
biennial examinations and cognitive performance at a single
occasion between examinations 14 or 15.
In a reanalysis of these data, poor performance was defined
as a score in the lower 50th percentile of the distribution of
test scores and risk of poor performance for each 10 mm Hg
in diastolic BP was estimated. Each 10 mm Hg increment in
diastolic BP was associated with a risk increment between
13% (OR, 1.13) and 14% (OR, 1.14) for the 4 memory tests.
Similar results were obtained for systolic BP. In a further
analysis, the never-treated hypertensive cohort was compared
to the normal BP cohort. The hypertensive group was at 41%
to 53% higher risk for poor performance across the episodic
and visual memory tests.25 The results cannot be explained
in terms of nonadherence to antihypertensive medications.
None of the hypertensive participants were treated and
none had a treatment history when admitted to the study 26
to 28 years earlier.
The work with the FHS was followed by studies of midlife
BP and late-life cognitive performance and dementia38–40
using the Honolulu-Asia Aging Study population. Midlife BP
was associated with lower cognitive performance and dementia assessed on 1 occasion later in life. In the dementia study
with 3703 Japanese-American men, the risk of dementia was
higher (OR, 4.8; 95% CI, 2.00 –11.00), when subjects with
systolic BP !160 mm Hg were compared to a reference group
of persons with systolic BP of 110 to 139 mm Hg.40
These and other prospective studies2,5,25,41 allow 4 generalizations: (1) relations between hypertension and cognition
are seen when exposure to hypertension in various studies
precedes the outcome by 10 to 20 years;2,25,38–41 (2) length of
exposure to hypertension is positively associated with the
magnitude of cognitive deficit; (3) lower cognitive performance cannot be explained away as a phenomenon related to
treatment with antihypertensive medications; and (4) relationships between hypertension and cognitive impairment are
stronger in untreated persons. The limitation in a number of
the studies summarized above was that cognitive performance and dementia were assessed only once after the
prospective surveillance period, but a number of longitudinal
studies of cognition that followed combined prospective
designs (BP and hypertension) with longitudinal analysis of
change over time.28,29

Expanding Knowledge and Improved
Methods (1996 –2011)
There were many new developments between 1996 and 2011,
including studies relating higher pulse wave velocity (a gold
standard index of arterial stiffness) to accelerated longitudinal
decline in cognitive performance scores, eg.42 We focus on
what we consider to be the most important research trends
among many other research advances during this period of
time.6,20,22–25

New Effect Modifiers
Age has been a target of research on effect modifiers of the
BP-cognition relationship since the Duke Longitudinal Study.
A concern for other cardiovascular disease (CVD) risk factors
that might modify relations between hypertension and cognitive functioning began in 1997 with the finding of significant
multiplicative interactions between hypertension/BP and diabetes mellitus in the FHS.26 The combined presence of these
risk factors was associated with lower cognitive performance
than the presence of either alone. The same effect modification result was reported in an FHS study of hypertension,
obesity, and cognitive performance where the statistical
effects of these risk factors were additive.43 Additive and
interactive risk factor effects have been seen in many studies
involving other CVD risk factors, including ApoE-#4 genotype.44 Clearly hypertension plays a role in concert with other
major CVD risk factors in the association between metabolic
syndrome and cognitive performance.44
In the Kungsholmen study of APOE, antihypertensive
medications served as modifiers of other important risk
factors for dementia.45 Compared with the presence of the
#3/#3 allele, presence of 1 or 2 APOE-#4 alleles increased the
risk of developing dementia, risk ratio (RR), 1.5; 95% CI, 1.1
to 2.1. For hypertensive individuals not using antihypertensive medications, the relative risk of dementia for APOE-#4
carriers was raised (RR, 2.2; 95% CI, 1.4 –3.4), but antihypertensive treatment was protective (RR, 0.9; 95% CI!,
0.5–1.6). The same pattern of results was observed when AD
was the outcome variable.

Mechanisms and Brain Regions
A continued expanding interest in mechanisms was accompanied by a major trend away from emphasis on the special
vulnerability of the prefrontal-brain regions to BP extremes,4,14 to a focus on structural and functional change over
a wide range of brain regions, ie, brain regions affected by
hypertension.46 Jagust et al,23 Jennings et al,3 Raz et al,14 and
Manolio et al4 provide reviews of the brain mechanism and
brain region literature in more depth than is possible here.
Studies by Kochunov et al47 and Gunstad et al48 illustrate a
renewed interest in genetic mechanism as intervening between BP and cognitive functioning.

Longitudinal Studies
Improvement in longitudinal methods may have been one of
the most important methodological advances in this time
period. Beginning in the mid-1980s, a wave of “post-Duke”
longitudinal studies of cognitive performance with 2 times of
measurement designs appeared in the literature,2,5,7,8,20 but
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Table 1.
Study
Skoog et al
(1996)55
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Longitudinal Studies With Three or More Examinations*
Age at
Baseline
70

Outcome Improving,
Declining, or No Change If
Not Significant Change

No. of Examinations

Result

Baseline%3 ages groups
with dementia over 15 y

Higher BP at age 70 was a risk factor for
dementia at age 79–85 y

BP related risk for dementia
was seen for persons over
79 y of age

Göteborg (Sweden)
Longitudinal/n!382

Study Sample

Elias MF et al
(1998)28

40–70

3 over 18 y

Individuals with higher BP at baseline and
over the entire study period showed more
decline in fluid cognitive performance
measures over time

Visualization/Fluid Subtests of
the WAIS

Maine Syracuse Longitudinal
Study/n!150

Swan et al
(1998)50

39–59

At least 10 exams over
20–30 y

Persons who maintained elevated BP over the
20–30 y tracking period were at higher risk
for lower performance levels

Verbal Learning and Memory
Function on the Iowa
Screening Battery

Western Collaborative Group
Study/n!717

Mean!83
(SD!2.3)

4 exams over 8 y

Diabetes related to decline- not hypertension,
but greatest decline for both diabetic and
hypertensive groups

Mental Status Evaluation with
MMSE

Origins of Variance in the Old-Old
Study/n!258

18–47

2–5 examinations over
19 y

Higher levels of baseline systolic and diastolic
BP and hypertension related to longitudinal
decline in a composite of fluid ability scores
but not crystallized ability

A composite of fluid ability
measures from the WAIS
including visualization spatial
ability

Maine Syracuse Longitudinal
Study/n!529

Hassing et al
(2004)56
Elias PK et al
(2004)29

47–83

Hebert et al
(2004)57

!65

4 exams over 7 y

No hypertension-associated decline

3-brief form tests of the
MMSE

Biracial Study Chicago/n!428

Insel et al
(2005)51

!65

4 exams over 7 y

Increasing BP (19 mm Hg systolic) related to
decline in performance in normal BP group

MMSE and the clock drawing
test

Hispanic Established Population for
Epidemiologic Study for the
Elderly/n!2859

Mean!70.6
(SD!8.3)

1 to 7 exams over 10 y

U-shaped relation between BP and decline

Multiple cognitive abilities

Baltimore Longitudinal
Study/n!847

65–94

3 annual exams over 3 y

Hypertension associated with more rapid
cognitive decline over time, logical reasoning
ability

Logical reasoning interpreted
as measuring executive
functioning

Advanced Cognitive Training for
Independent and Vital Elderly
trial/n!2802

76.8 (0.03)

1 to 58 mo

Nondemented and demented status at
baseline—antihypertensive medications were
associated with lower rate of decrement over
time for MMSE and measures of executive
functioning

MMSE and measures of
executive functioning

Hispanic Established Population
Study of the Elderly/n!258

45–64

4 cognitive assessments
over 14 y beginning in
1990–1992 and
2004–2006

Hypertension associated with cognitive decline

Word fluency delayed
(executive function), word
recall and digit symbol
substitution for both groups

ARIC cohort/n!1130

Waldstein et al
(2005)49
Kuo et al
(2005)52
Hajjar et al
(2005)53

Knopman et al
(2009)54

*Other incident dementia studies are cited in text. Skoog et al55 are cited in the table because there was a follow-up with 3 distinct age groups.
BP indicates blood pressure; MMSE, Mini-Mental State Examination; WAIS, Wechsler Adult Intelligence Scale.

this design does not allow the examination of possible
nonlinear change in cognitive performance over time.49 A
pivotal set of longitudinal studies (Table) with at least 3 times
(waves) of measurement began to appear in 1996.2 In
928,29,49–55 of these 1128,29,49–57 studies, hypertension and/or
increments in BP (systolic, diastolic, or MAP) were statistically significant predictors of progressive decline in performance (linear and nonlinear) over time. This was true for
predictions of decline in cognitive function from baseline BP
(systolic and diastolic) and hypertension where follow-up of
cognitive functioning ranged from a total of 352 to 30 years.50
The hypertension and BP-associated decline in cognitive
performance reported in these studies (Table) was seen with
control for stroke, dementia, CVD risk factors, comorbidity,
and antihypertensive treatment. Controls (including for treatment) involved exclusion, stratification, and statistical adjustment depending on the specific study.
The cognitive domains for which decline was reported
paralleled those identified in cross-sectional work, ie, global
performance and multiple specific cognitive abilities with the
exception of overlearned and well-practiced verbal abilities
(crystallized ability).2,5,25 Concern for at least 3 times of
serial measurement is reinforced by the Baltimore Longitudinal Study of Aging.49 Waldstein and colleagues reported
nonlinear relations between hypertension/BP and cognitive
performance and a J-shaped relation between BP and perfor-

mance,49 thus confirming the importance of studies with more
than 2 times of measurement.
The longitudinal study by Skoog et al55 was particularly
important to a swing from an emphasis on hypertension in
VaD to a recognition of its importance in AD. In 1983, St.
Clair and Whalley58 published their now classic paper on the
importance of hypertension in multi-infarct disease. At this
time the presence of vascular disease, including hypertension,
was an exclusion for the diagnosis of AD.59 A study by Skoog
et al55 in 1996 and a second by Hoffman et al60 in 1997 with
the Rotterdam sample played pivotal roles in revisions of the
recognition of hypertension and associated CVD risk factors
as important predictors of AD. Skoog et al55 followed 382
participants free from dementia at age 70 through the age
intervals of 70 to 75, 75 to 79, and 79 to 85. Those who
developed dementia from age 70 to 85 years exhibited higher
systolic BP and diastolic BP at age 70. In 10 of the 18
participants who developed dementia between 79 and 85,
high BP at age 70 was associated with AD. In the Rotterdam
study (n!1982) published 1 year later, indices of atherosclerosis, including ankle-brachial systolic BP levels, were
associated with VaD and AD.60 Moreover, the prevalence
of each increased with the severity of atherosclerotic
disease. These studies had a significant impact on revision
of definition of VaD59 and recognition of the importance of
hypertension in AD.
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Although changes in cognitive performance over time and
dementia have been studied longitudinally, there has been
much less work on clinically recognized cognitive impairment that falls short of dementia. In 2007, Reitz et al61
addressed the question of whether the risk of MCI is
increased by hypertension. Baseline data were obtained for
918 individuals (mean age!76 years) between 1992 and
1994 and followed by data collection at the following
periods: 1994 to 1996; 1996 to 1997; 1997 to 1999. During
the longitudinal surveillance period, 160 cases of amnestic
MCI and 174 cases of nonamnestic MCI were diagnosed.
Hypertension was associated with increased risk of all-cause
MCI (hazard ratio, 1.40; 95% CI, 1.06 to 1.77) and nonamnesic MCI (hazard ratio, 1.70; 95% CI, 1.13 to 2.42), after
adjusting for age and sex and remained similar with additional adjustment for education and APOE-#4 genotype.
These associations were modestly attenuated when adjusted
for stroke, diabetes, LDL cholesterol, smoking or heart
disease, and use of antihypertensive medications. Alcohol
consumption and depressed mood were not included in the
covariate sets. After adjusting for stroke and other CVD risk
factors there was no significant association between hypertension and amnestic MCI.
Four years later, using the Canadian Study of Health and
Aging study population, Oveisgharan and colleagues,62 using
2 waves of assessment (1991, 1991–1996), examined incident
dementia for 990 elderly (mean age!83 years at baseline)
participants defined as cognitively impaired but no dementia.
No association between hypertension and progression to
dementia was found for participants with memory dysfunction alone or in combination with executive dysfunction.
However, among subjects with executive dysfunction alone,
58% with hypertension, as compared to 28% with normal BP,
progressed to dementia. The authors speculated that control
of hypertension might prevent progression to dementia in
one-third of individuals with cognitive impairment but no
dementia. Clinical trials are needed to verify this conclusion
but taken together the studies are pivotal with regard to
studying hypertension-related change in cognitive performance as it progresses from nonclinical deficit, to MCI, and
then to dementia.

Randomized to Treatment and Placebo Clinical
Trials
Excluding trials with no placebo and crossover designs, the
first clinical trials designed for the dual purpose of lowering
BP and improving cognitive performance using a battery of
psychometric test scores were seen in 1996. In a trial
published by the Medical Research Council in older adults
(65–75 years),63 participants were randomly assigned to
diuretic (hydrochlorothiazide plus amiloride), beta blocker
(atenolol), or placebo arms. For a period of 54 months, 2584
participants were administered a battery of 4 psychometric
tests. No statistically significant differences among active
arms were observed. However, a follow-up of 387 surviving
participants for 9 to 12 years indicated that less decline in
systolic BP was associated with poorer cognitive performance on multiple cognitive performance tests with adjust-

ment for family history of dementia, cognitive performance at
baseline, age, and alcohol consumption.64
The first large sample (n!4736; mean age 72 years)
randomized to treatment and placebo clinical trials with a
dementia outcome, the Systolic Hypertension in the Elderly
Program (SHEP), was published in 1994.65 Active treatment
with a diuretic (Chlorthalidone), and addition of Atenolol or
Reserpine if necessary to achieve BP lowering goals, had no
statistically significant effect on incident dementia. The
SHEP study was followed by the double-blind placebo
controlled Syst-Eur study with 2418 participants (mean
age!70).66 Active treatment consisted of the dihydropyridine
calcium channel blocker nitrendipine, which could be combined with enalapril, hydrochlorothiazide, or both to achieve
BP control. This trial was terminated after a median of 2 years
because active treatment was associated with a 42% decrease
in fatal and nonfatal stroke. Active treatment reduced diastolic BP by 3.8 mm Hg, systolic BP by 8.3 mm Hg and
incident dementia by 50%, from 7.7 to 3.8 dementia cases per
1000 patient years (P!0.05). After termination of the trial, all
of the participants were offered open label treatment with the
same active medication, thus lengthening follow-up to 3.9 years
and increasing the number of AD cases from 32 to 64.67
Immediate versus delayed antihypertensive therapy reduced the
risk of dementia by 55%, and from 7.4 to 3.3 cases per 1000
patient years (P#0.05). Recent meta-analyses place positive
results for these studies in the context of multiple studies that
followed. For example, a 2007 meta-analysis, including 4
placebo-controlled trials for prevention of dementia, SHEP,
Syst-Eur, PROGRESS, and SCOPE, reported a common OR of
0.89 (95% CI, 0.75–1.04; P!0.15).7 In 2011 the meta analysis
was updated and included ADVANCE, HYVET-COG, PRoFESS, and TRANSCEND trials.68 In all trials combined there
was no significant reduction in risk of dementia (approximately 5%), but for trials involving a diuretic or dihydropyridine calcium channel blocker as part of treatment, the
reduction was significant (approximately 18%). Authors of
the 2011 meta-analysis point out that differences between
drug classes may be explained by the amount of BP
reduction. Weighted meta-regression analysis indicted that
lowering of systolic BP accounted for 41% of the variance
in risk reduction. It is clear from these studies and other
meta-analyses and reviews of the literature69 that the issue
of whether BP lowering with antihypertensive medications
improves cognitive performance or decreases the risk of
dementia has not been resolved.

Trials of Nondrug Therapies

A small trial by Smith et al70 provides preliminary evidence
that a combination of structured diet, exercise, and counseling, compared to treatment as usual, lowers BP and is
associated with a parallel modest improvement in cognitive
performance in younger and middle-aged adults presenting
with either prehypertension BP values or modestly elevated
BP values.70

Translation and Perspectives
The literature on hypertension and cognition strongly supports the need to treat hypertension early and aggressively, ie,
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the brain is a target organ for hypertension and once morphological and functional changes have begun, restoration of
cognitive functioning may be more difficult.3 Lowered cognitive performance has serious implications for quality of life
and healthcare costs at all ages. Sustaining one’s level of
cognitive performance over the lifespan may be an important
motivation for patients to engage in preventive measures and
adherence to drug treatment protocols. Results of clinical
trials of antihypertensive medications are mixed. Positive
changes in performance are modest when reported, but the
progress of dementia has been slowed in a few major trials.
The modest results obtained must be considered in relation to
the fact that hypertension works its influence on cognitive
performance in concert with other CVD risk factors,44 and
trials are conducted for relatively short periods of time
relative to the long period of time involved in the progression
from hypertension to dementia.
The termination of trials once BP lowering goals are
reached does not allow the opportunity to examine success
rates for cognitive restoration over longer and more meaningful periods of time, albeit ethical issue concerns do require
a more sophisticated design. Clearly, adding a limited cognitive test battery in a study designed primarily to examine BP
lowering is insufficient. The meta-analyses and reviews
suggest the need to focus more on specific antihypertensive
medications and drug classes in future studies, and to consider the extent to which medications lower BP.6,68,70 Cognition must take on more importance as a hypertensionrelated outcome given the dramatic rise in prevalence and
incidence of dementia projected for developed and developing countries.68
History teaches us that hypertension-related cognitive impairment is not a problem of old age, but a problem at all
ages. There is a legitimate concern for initiating antihypertensive therapy in young adults who then must face a lifetime
of treatment with antihypertensive medication. Preliminary
studies indicate that structured diet and exercise programs
may be effective in lowering mild and prehypertensive BP
values and improving cognitive performance70; major
clinical trials of lifestyle interventions are needed. Sine
remediis medicina debilis est. Without remedies medicine
is powerless.
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